Dement Neurocogn Disord.  2018 Mar;17(1):37-40. 10.12779/dnd.2018.17.1.37.

Emerging of Explosive Speech after Olanzapine in Multiple System Atrophy Patient

• Kim YS
• Kim SJ
• Lee J
• Kim HJ

• KMID: 2442816
• DOI: http://doi.org/10.12779/dnd.2018.17.1.37

Abstract

BACKGROUND
Cerebellum has an important role in sensorimotor control including speech. Multiple system atrophy (MSA) is a sporadic and rapidly progressive neurodegenerative disorder that presents with autonomic failure in combination with Parkinsonism or cerebellar ataxia.
CASE REPORT
We report a case of MSA-cerebellum subtype associated with emergence of irreversible explosive speech following olanzapine therapy.
CONCLUSIONS
Further investigation into speech problems in MSA according to subtype and disease severity is needed, and side effects of olanzapine therapy should also be considered.

Keyword

Antipsychotic Agents; Multiple System Atrophy; Speech

MeSH Terms

Antipsychotic Agents
Cerebellar Ataxia
Cerebellum
Humans
Multiple System Atrophy*
Neurodegenerative Diseases
Parkinsonian Disorders
Antipsychotic Agents

Figure

• 

  Fig. 1 T2-weighted FLAIR MRI. (A) Severe atrophy of the pontocerebellar region with hot-cross bun sign (arrow). (B, C) Axial and coronal sections showing atrophic changes in the bilateral frontal area predominantly on the left side (open arrow). (D) Midline sagittal section showed prominent pontocerebellar atrophy. These atrophic changes were observed via voxel-based morphometry (false discovery rate, p<0.05). FLAIR: fluid attenuated inversion recovery, MRI: magnetic resonance imaging, RT: right side, LT: left side.

Reference

1. Manto M, Bower JM, Conforto AB, Delgado-Garcia JM, da Guarda SN, Gerwig M, et al. Consensus paper: roles of the cerebellum in motor control--the diversity of ideas on cerebellar involvement in movement. Cerebellum. 2012; 11:457–487.

2. Mariën P, Ackermann H, Adamaszek M, Barwood CH, Beaton A, Desmond J, et al. Consensus paper: language and the cerebellum: an ongoing enigma. Cerebellum. 2014; 13:386–410.

3. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol. 2009; 8:1172–1178.

4. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51:1546–1554.

5. Chang CC, Chang YY, Chang WN, Lee YC, Wang YL, Lui CC, et al. Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol. 2009; 16:1144–1150.

6. Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm (Vienna). 2013; 120:613–618.

7. Riecker A, Mathiak K, Wildgruber D, Erb M, Hertrich I, Grodd W, et al. fMRI reveals two distinct cerebral networks subserving speech motor control. Neurology. 2005; 64:700–706.

8. Jürgens U. Neural pathways underlying vocal control. Neurosci Biobehav Rev. 2002; 26:235–258.

9. Brady JP. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol. 1998; 18:50–54.

10. Gaile S, Noviasky JA. Speech disturbance and marked decrease in function seen in several older patients on olanzapine. J Am Geriatr Soc. 1998; 46:1330–1331.

11. Granger AS, Hanger HC. Olanzapine: extrapyramidal side effects in the elderly. Aust N Z J Med. 1999; 29:371–372.

12. Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp Optom. 2014; 97:483–491.

13. Gustaw K, Gonet W. Speech disorders in multiple system atrophy of parkinson type. Clin Res. 2007; 1:185–188.